Realfiction (REALFI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
27 Aug, 2026Executive summary
Revenue declined 24% year-over-year in Q2-2026 to SEK 856k, reflecting a strategic focus on DPT commercialization and reduced legacy product sales.
Gross profit margin improved to 77.3% in Q2-2026 from 65.4% in Q2-2025 due to a favorable sales mix.
Operating loss narrowed to SEK -5.3m in Q2-2026 from SEK -6.6m in Q2-2025, driven by cost reductions.
Liquidity remains challenging; a SEK 2m bridge loan was secured, and a rights issue of up to SEK 36m is planned.
The company’s ability to continue as a going concern depends on the successful completion of the rights issue.
Financial highlights
Q2-2026 revenue: SEK 856k (Q2-2025: SEK 1,132k); H1-2026 revenue: SEK 1,667k (H1-2025: SEK 2,006k).
Q2-2026 gross profit: SEK 662k (Q2-2025: SEK 740k); gross margin: 77.3% (Q2-2025: 65.4%).
Q2-2026 result after financial items: SEK -6,377k (Q2-2025: SEK -7,662k).
Cash flow from operating activities in H1-2026: SEK -7,534k (H1-2025: SEK -11,101k).
Equity at 30 June 2026: SEK 36,740k (Q2-2025: SEK 33,822k).
Outlook and guidance
Rights issue, if successful, is expected to provide liquidity until June 2027.
Focus remains on validating the nematic SLM approach and advancing strategic partnerships.
Further development of larger DPT platforms contingent on additional customer funding.
Latest events from Realfiction
- Nematic SLM validation is key to unlocking commercialization, with rights issue as sole financing path.REALFI
Investor update - Liquidity risk persists as DPT commercialization lags and early loan repayments strain cash flow.REALFI
Q1 2026 - Sharp revenue decline and liquidity risks as focus shifts to DPT commercialization.REALFI
Q4 2025 - Sharp revenue drop in Q3 as DPT sales paused; capital raised to support DPT commercialization.REALFI
Q3 2025 - SEK 50 million rights issue supports commercialization of advanced glasses-free 3D display tech.REALFI
Status Update - DPT commercialization advances with improved margins and new funding, despite lower revenue.REALFI
Q2 2025 - Q3-2024 saw record DPT-driven revenue growth and strong gross margins, with liquidity secured.REALFI
Q3 2024 - Q2-2024 saw strong revenue growth and DPT licensing talks nearing a breakthrough.REALFI
Q2 2024 - DPT commercialization accelerates with new funding and industry milestones despite lower revenue.REALFI
Q1 2025